随着市场对该领域兴趣重燃，预期复星医药股价将出现正面反应，但此举可能加剧国内同业拓展海外业 务时的竞争压力。该行上调复星医药盈利预测，将2025至27年各年纯利预测分别上调1%、2.4%及 1.9%，以反映交易的财务影响；同时将H股目标价由29.6港元升至31.6港元，A股目标价由40.2元升至 42.4元，重申"跑赢大市"评级。 复星医药旗下临床前小分子GLP-1药物与辉瑞签署21亿美元合作协议。里昂发表报告指，由于辉瑞在 GLP-1领域的积极参与及长期布局，此次合作使YP05002处于领先地位。相较同类授权协议，财务条款 亦属合理。 ...

格隆汇12月10日｜复星医药A股一度涨近5%报28.8元，H股一度涨近7%报22.94港元。消息面上，公司 昨晚公告，控股子公司药友制药与辉瑞于2025年12月9日签订《许可协议》，药友制药就口服小分子胰 高血糖素样肽-1受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品授予辉瑞于全球范围及领 域(人类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化权利。药友制药将有权 获得不可退还的首付款1.5亿美元及至多3.5亿美元的开发里程碑款项。此外，基于许可产品的年度净销 售额达成情况，辉瑞将向药友制药支付至多15.85亿美元的销售里程碑款项。该协议自2025年12月9日起 生效。 ...

复星医药 在陆港两地上涨，A股和港股分别上涨近4%和近6%。此前公司公告称，子公司与辉瑞就GLP- 1R激动剂签订许可协议，最高可获5亿美元。 ...

Core Insights - The newly released "Commercial Health Insurance Innovative Drug Directory (2025)" marks the first of its kind in China, focusing on high-innovation drugs that exceed the basic medical insurance's scope [1][2] Group 1: Overview of the Commercial Health Insurance Innovative Drug Directory - The directory was developed by the National Healthcare Security Administration and includes high-priced innovative drugs, gene therapies, and specific rare disease treatments [1] - A total of 121 drug names were reviewed, with 19 drugs from 18 innovative pharmaceutical companies successfully included, resulting in an acceptance rate of approximately 15.7% [1] Group 2: Focus on Rare Diseases and Cancer Treatments - The directory includes drugs for Alzheimer's disease and rare diseases prevalent in children, such as Gaucher disease and neuroblastoma [2] - North Sea Kangcheng's Gaucher drug, the first domestically developed enzyme replacement therapy, was approved for use in patients aged 12 and older [2] Group 3: Impact on CAR-T Therapy - Five domestic CAR-T products were included in the directory, which is expected to significantly reduce patient out-of-pocket expenses and improve accessibility [3] - The inclusion of CAR-T products is seen as a milestone that will positively impact the entire industry chain, with companies planning to expand domestic supplier partnerships to enhance supply chain efficiency [3]

每经AI快讯，12月10日，复星医药A股和H股分别上涨近4%和近6%。 （文章来源：每日经济新闻） ...

每经AI快讯，复星医药(02196.HK)高开逾4%，截至发稿涨4.19%，报22.38港元，成交额857.15万港元。 （文章来源：每日经济新闻） ...

每经AI快讯，12月10日，复星医药(02196.HK)涨超6% ，股价报22.82港元。 ...

Core Viewpoint - Fosun Pharma's stock price increased by 5.96% to HKD 22.76 following the announcement of a licensing agreement with Pfizer for the development of the oral GLP-1 receptor agonist YP05002 [2][6]. Group 1: Licensing Agreement - Fosun Pharma's subsidiary,药友制药, and Fosun Pharma Industry signed a licensing agreement with Pfizer on December 9, 2025, granting Pfizer exclusive rights to develop, use, manufacture, and commercialize YP05002 globally for all human and animal indications [2][6]. - As part of the agreement,药友制药 will receive a non-refundable upfront payment of USD 150 million and up to USD 350 million in milestone payments based on clinical and commercialization progress of the licensed product [2][6]. Group 2: Product Details - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, aimed at treating type 2 diabetes, obesity, and related diseases [3][7]. - The drug works by activating GLP-1 receptors to promote insulin secretion, reduce glucagon secretion, inhibit gastric emptying, and suppress appetite, thereby aiding in weight management and treating metabolic disorders [3][7]. - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [3][7].

Group 1 - Fosun Pharma (02196) opened over 4% higher, currently up 4.19% at HKD 22.38, with a trading volume of HKD 8.5715 million [1] - The company announced a licensing agreement with Pfizer on December 9, 2025, allowing Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist (including YP05002) globally for all human and animal indications [1] - Under this agreement, Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of USD 150 million and up to USD 350 million in milestone payments based on the clinical and commercialization progress of the licensed product [1] Group 2 - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, designed to treat type 2 diabetes, obesity, and related diseases by promoting insulin secretion and reducing glucagon secretion [2] - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2] - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [2]

Industry News - A new polysilicon platform company named Beijing Guanghe Qiancheng Technology Co., Ltd. has been registered with a capital of 3 billion, established on December 9, 2025, in Beijing. The company aims to explore potential strategic cooperation opportunities within the industry, such as technology upgrades and market expansion [25][25]. - The National Retail Innovation Development Conference is being held in Beijing from December 9 to 10. The Deputy Minister of Commerce, Sheng Qiuping, emphasized the need for further improvement in retail layout, supply-demand matching, and online-offline balance, while also encouraging the development of new business models and scenarios to stimulate consumer potential [25][25]. - The State Administration for Market Regulation has approved the release of two mandatory national standards for civil unmanned aerial vehicles, which will take effect on May 1, 2026 [25][25]. - Alibaba has established the Qianwen C-end Business Group, aiming to develop Qianwen into a super app and the primary entry point for users in the AI era [26][26]. - Huawei's 2012 Lab has established a foundational model department focused on advancing base model development and is actively recruiting young research talents with outstanding academic backgrounds [26][26]. - The Ministry of Agriculture and Rural Affairs reported that pork supply in November was sufficient, with prices slightly decreasing. The average daily market volume of pork in Beijing's Xinfadi market was 2,128.8 heads, a 10.57% increase from October and a 7.54% increase year-on-year [26][26]. - The National Development and Reform Commission indicated that the coking coal market shifted from tight to loose in November, with price expectations declining. The coking coal price expectation index fell to below the 50% threshold, indicating weak support for the market [26][26]. Company News - Jiaao Environmental Protection announced that due to false records in the 2022 and 2023 annual reports, the company's stock will be subject to other risk warnings [27][27]. - Huilun Crystal also announced that its 2021 and 2022 annual reports contained false records, leading to similar risk warnings for its stock [27][27]. - Haiguang Information announced the termination of its major asset restructuring with Zhongke Shuguang [28][28]. - Zhongke Shuguang announced the termination of its share swap absorption merger with Haiguang Information and the associated fundraising [29][29]. - Tianyuan Dike announced that its chairman, Chen You, has been placed under detention [30][30]. - Lain Biological announced that its controlling shareholder is planning a change of control and intends to acquire at least 80% of Beijing Jinkangpu's shares, leading to a stock suspension [30][30]. - Shengyi Technology announced an investment of approximately 198 million yuan to build an annual production project of 2,400 tons of ultra-high molecular weight polyethylene fiber, expanding its application value in humanoid robots [30][30]. - HoloWave announced a significant increase in orders for satellite testing systems, primarily from commercial aerospace satellite manufacturers and testing service providers [30][30]. - Longi Green Energy announced the termination of its overseas issuance of global depositary receipts [31][31]. - Zaiseng Technology announced that its controlling shareholder, Guo Mao, plans to transfer 6.04% of the company's shares to Zhongrong Huaxin [31][31]. - Si Rui Pu announced the termination of its plan to acquire shares of Aola, and its stock will resume trading [32][32]. - Fosun Pharma announced that its subsidiary, Yaoyou Pharmaceutical, has signed a licensing agreement with Pfizer [33][33].